Diligence memo · auto-generated · as of July 2, 2026
Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Scinai Immunotherapeutics Ltd. operates in Pharmaceuticals, based in JERUSALEM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Scinai Immunotherapeutics Ltd. has raised $3.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.7M on 2023-12-29.
Most recent recorded round closed around 2023-12-29.
Valuation (modeled)modeled
Provath models Scinai Immunotherapeutics Ltd. at approximately $10M (range $1.3M–$32M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.09× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era. Within the normal band (109% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 34% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 18% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.